Simlukafusp alfa
- Generic Name
- Simlukafusp alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1776942-10-9
- Unique Ingredient Identifier
- FL08SGO9XA
- Background
RO6874281 is under investigation in clinical trial NCT03193190 (A Study of Multiple Immunotherapy-based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-pancreatic Cancer)).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 83
- Registration Number
- NCT03875079
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇫🇷Centre Eugene Marquis; Service d'oncologie, Rennes, France
🇫🇷Institut Gustave Roussy; Dermatologie, Villejuif, France
Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 256
- Registration Number
- NCT03386721
- Locations
- 🇫🇷
ICM; Medecine B3, Montpellier cedex 5, France
🇬🇧Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom
🇹🇷Adana Baskent University Hospital; Medical Oncology, Adana, Turkey
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
- Conditions
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 340
- Registration Number
- NCT03193190
- Locations
- 🇺🇸
Uni of Chicago Medical Center; Room M454, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
- Conditions
- Interventions
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 69
- Registration Number
- NCT03063762
- Locations
- 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇫🇷Centre Léon Bérard - Centre régional de lutte contre le cancer Rhône-Alpes, Lyon, France
🇮🇹Universita di Modena e Reggio Emilia;Dipartimento di Oncologia ed Ematologia, Modena, Emilia-Romagna, Italy
A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
- Conditions
- Interventions
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 134
- Registration Number
- NCT02627274
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸UCSD - Moores Cancer Center, La Jolla, California, United States
🇨🇦Princess Margaret Cancer Center, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.